Abstract

BackgroundThe use of stereotactic body radiation therapy (SBRT) for tumor and pain control in patients with bone metastases is increasing. We report response assessment after bone SBRT using radiological changes through time and clinical examination of patients.MethodsWe analyzed retrospectively oligo-metastatic/progressive patients with bony lesions treated with SBRT between 12/2008 and 10/2018, without in-field re-irradiation, in our institution. Radiological data were obtained from imaging modalities used for SBRT planning and follow-up purposes in picture archiving and communication system and assessed by two independent radiologists blind to the time of treatment. Several radiological changes were described. Radiographic response assessment was classified according to University of Texas MD Anderson Cancer Center criteria. Pain response and the neurological deficit were captured before and at least 6 months after SBRT.ResultsA total of 35 of the 74 reviewed patients were eligible, presenting 43 bone metastases, with 51.2% (n = 22) located in the vertebral column. Median age at the time of SBRT was 66 years (range 38–84) and 77.1% (n = 27) were male. Histology was mainly prostate (51.4%, n = 18) and breast cancer (14.3%, n = 5). Median total radiation dose delivered was 24 Gy (range 24–42), in three fractions (range 2–7), prescribed to 70–90% isodose-line. After a median follow-up of 1.8 years (range < 1–8.2) for survivors, complete or partial response, stable, and progressive disease occurred in 0%, 11.4% (n = 4), 68.6% (n = 24), and 20.0% (n = 7) of the patients, respectively. Twenty patients (57.1%) died during the follow-up time, all from disease progression, yet 70% (n = 14) from this population with local stable disease after SBRT. From patients who were symptomatic and available for follow-up, almost half (44.4%) reported pain reduction after SBRT.ConclusionsEighty percent of the patients showed local control after SBRT for bone metastases. Pain response was favorable. For more accurate response assessment, comparing current imaging modalities with advanced imaging techniques such as functional MRI and PET/CT, in a prospective and standardized way is warranted.Trial registration Retrospectively registered.

Highlights

  • The use of stereotactic body radiation therapy (SBRT) for tumor and pain control in patients with bone metastases is increasing

  • There are specific aspects to consider in the interpretation of radiological changes after SBRT, including pseudoprogression, vertebral compression fracture (VCF), epidural progression, changes in bone density depending on the nature of metastasis and altered vascularization

  • Population A total of 35 patients, 27 (77.1%) males and 8 (22.9%) females with 43 bone metastases were analysed in this cohort

Read more

Summary

Introduction

The use of stereotactic body radiation therapy (SBRT) for tumor and pain control in patients with bone metastases is increasing. We report response assessment after bone SBRT using radiological changes through time and clinical examination of patients. Bone metastases are predominantly located in the vertebral column and it is estimated that over 10% of cancer patients develop symptoms at this site [3, 4]. The role of radiotherapy in palliating pain for bone metastases is well established [5]. Patients with painful bone metastases had a limited median overall survival (OS) of 7–9 months [6,7,8]. The pain response is the focus of these prospective randomized trials and none of them has reported the radiological response assessment yet. There are specific aspects to consider in the interpretation of radiological changes after SBRT, including pseudoprogression, vertebral compression fracture (VCF), epidural progression, changes in bone density depending on the nature of metastasis and altered vascularization

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.